[
    [
        {
            "time": "",
            "original_text": "关注低估值、低位置血制品、消费医疗板块，重点推荐博雅生物、鱼跃医疗等!【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "低估值",
                    "血制品",
                    "消费医疗",
                    "博雅生物",
                    "鱼跃医疗"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "关注低估值、低位置血制品、消费医疗板块，重点推荐博雅生物、鱼跃医疗等!【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "“药明系”悍将王少雄蝶变 美康生物联合博威生物发力CDMO",
            "features": {
                "keywords": [
                    "药明系",
                    "王少雄",
                    "美康生物",
                    "博威生物",
                    "CDMO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“药明系”悍将王少雄蝶变 美康生物联合博威生物发力CDMO",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业跨市场周报：关注高景气度赛道的超预期机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "高景气度",
                    "超预期机会"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：关注高景气度赛道的超预期机会",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "重大发现！与穴位密切相关！中国科学家团队首次发现人体存在；逾13亿美元研发新一代，双特异性抗体疗法，杨森达成合作丨贝壳日报",
            "features": {
                "keywords": [
                    "重大发现",
                    "穴位",
                    "双特异性抗体",
                    "杨森合作"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医疗研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "重大发现！与穴位密切相关！中国科学家团队首次发现人体存在；逾13亿美元研发新一代，双特异性抗体疗法，杨森达成合作丨贝壳日报",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "干货！2021年中国医药研发外包(CRO)行业龙头企业对比：药明康德VS康龙化成 谁是中国CRO之王？",
            "features": {
                "keywords": [
                    "医药研发外包",
                    "CRO",
                    "药明康德",
                    "康龙化成"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "研发外包"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "干货！2021年中国医药研发外包(CRO)行业龙头企业对比：药明康德VS康龙化成 谁是中国CRO之王？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]